Several analysts have recently updated their ratings and price targets for Anavex Life Sciences Corp. (NASDAQ: AVXL):

  • 8/10/2017 – Anavex Life Sciences Corp. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.75 price target on the stock. According to Zacks, “ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company’s proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. “
  • 8/9/2017 – Anavex Life Sciences Corp. had its “buy” rating reaffirmed by analysts at Noble Financial.
  • 8/7/2017 – Anavex Life Sciences Corp. was given a new $15.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 8/3/2017 – Anavex Life Sciences Corp. was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/20/2017 – Anavex Life Sciences Corp. had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $15.00 price target on the stock. They wrote, “Anavex announced the appointment of Andrew J. Cole, M.D., F.R.C.P.(C.) to its Scientific Advisory Board. Normally we would not comment on an advisory board addition however we are quite impressed with Dr. Cole and we believe his role represents a real element of validation to the company. Dr. Andrew J. Cole is Director of the MGH Epilepsy Service, Chief of the Division of Clinical Neurophysiology and Epilepsy and Professor of Neurology at Harvard Medical School. He graduated from Dartmouth College Magna Cum Laude and Dartmouth Medical School. He trained in Neurology and Clinical Neurophysiology at the Montreal Neurological Institute, and then moved to Johns Hopkins University School of Medicine where he was Assistant Professor of Neurology. He came to Massachusetts General Hospital in 1992 where he started and developed the MGH Epilepsy Service and founded the MGH Pediatric Epilepsy Service. He has published extensively in clinical neurology, epilepsy, clinical neurophysiology and basic neuroscience. In addition to research and clinical work, Dr. Cole lectures frequently throughout the United States and internationally, and has been a visiting professor at numerous institutions in the U.S.A. and abroad. I am impressed with Anavex and its potential CNS platform drug, ANAVEX 2-73, which has shown encouraging clinical safety data combined with promising preclinical anti-seizure data,” said Andrew J. Cole, M.D., F.R.C.P.(C.), Director of the Massachusetts General Hospital Epilepsy Service and Professor of Neurology at Harvard Medical School.””
  • 7/12/2017 – Anavex Life Sciences Corp. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company’s proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. “
  • 6/30/2017 – Anavex Life Sciences Corp. was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.

Shares of Anavex Life Sciences Corp. (AVXL) traded up 14.21% during trading on Monday, reaching $4.10. 531,705 shares of the company traded hands. The firm’s market capitalization is $172.91 million. The firm has a 50-day moving average price of $4.72 and a 200-day moving average price of $5.42. Anavex Life Sciences Corp. has a 12 month low of $2.43 and a 12 month high of $6.64.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Equities research analysts anticipate that Anavex Life Sciences Corp. will post ($0.37) EPS for the current year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.